The US Food and Drug Administration (FDA) has declared an end to the shortage of tirzepatide, the active ingredient in Eli ...

Wegovy and Zepbound are still hard to get. Knockoff versions from Noom, Ro, and others are filing in the gaps.

Ilant estimates that behavioral therapy can help many people lose up to 5% of their weight, anti-obesity medications can help ...

Glucagon-like peptide 1 receptor agonists, more commonly known as GLP-1 medications, have dominated headlines for their ...

The U.S. Food and Drug Administration said Eli Lilly's diabetes and weight-loss drugs marketed as Zepbound and Mounjaro are no longer in shortage, signaling that the company has succeeded in expanding ...

Tirzepatide, a dual GIP and GLP-1 receptor agonist, has gained widespread recognition for its effectiveness in promoting substantial weight loss by enhancing metabolic functions and controlling ...

Cramer remains steadfast on Eli Lilly and Company (NYSE:LLY) as per Mad Money’s episode on September 30. Despite there being ...

It took GLP-1 medications like Ozempic just seven years to surpass insulin as the the second most common treatment for type 2 ...

As Eli Lilly has surged to become the most valuable company in biopharma—with a market cap now more than twice that of ...

In real-world settings multiple factors contribute to non-persistence, including adverse effects, high cost-sharing and ...

In 1988, Oprah pulled a wagon with 67 pounds of fat, showcasing her weight loss. Fans now wonder if she'll consider GLP-1 for control.

A new study published in the journal JAMA Network Open found that food left in the stomach or stool left in the bowel can ...